C3 Glomerulopathy: recent advances and an update on management
Open Access
- 1 June 2026
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (2) , e20250306
Abstract
C3 glomerulopathy (C3G) is a clinicopathologic entity characterized by glomerular inflammation with dominant staining for C3 on immunofluorescence microscopy. Electron microscopy is used to determine the location and type of deposits, which further divides C3G into C3 glomerulonephritis (C3GN) and dense deposit disease (DDD) based on ultrastructural findings. Both entities are progressive, with about 60% of patients progressing to end-stage kidney disease (ESKD) within 10 years. Recurrence after kidney transplantation occurs in up to 60% of C3G cases. New knowledge about the pathophysiology—different patterns of injury, histopathological scoring, apolipoprotein E staining, dysregulation of the alternative complement pathway (including both autoantibodies to and mutations in complement regulatory factors), as well as proteomic analyses—has allowed a better understanding of different pathophysiological profiles and clinical presentations, enabling individualized treatment. The role of nephroprotection is well established in C3G, as it is for other glomerular diseases. Non-specific treatment with corticosteroids and immunosuppression is associated with a variable response rate. However, more recently, results from clinical trials with proximal complement inhibitors have shown significant improvement in proteinuria and attenuation of the decline in estimated glomerular filtration rate (eGFR). Based on the results of these trials involving drugs that specifically target the upstream complement pathways, including the alternative pathway, new treatment options have recently become available for patients with C3G.Keywords
This publication has 40 references indexed in Scilit:
- Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative GlomerulonephritisKidney International Reports, 2024
- Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathyKidney International, 2024
- Efficacy and Safety of Iptacopan in Patients With C3 GlomerulopathyKidney International Reports, 2023
- Complement inhibitors in pediatric kidney diseases: new therapeutic opportunitiesPediatric Nephrology, 2023
- Overlap of C3 Glomerulopathy and Thrombotic Microangiopathy: A Case SeriesKidney International Reports, 2022
- Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney International, 2021
- C3 glomerulopathy associated with monoclonal Ig is a distinct subtypeKidney International, 2018
- C3 glomerulonephritis with a severe crescentic phenotypePediatric Nephrology, 2017
- Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2017
- Eculizumab and recurrent C3 glomerulonephritisPediatric Nephrology, 2013